Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BlueprintMeds
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BlueprintMeds
-
We’re committed to advancing
#precisontherapy for the#GIST community. Learn more about our clinical programs: http://bit.ly/2v1hVzy#ESMOsarcoma20Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At
#ESMOsarcoma20 in Milan, Italy, we’re thrilled to meet with key clinical leaders in#sarcoma and#GIST: http://bit.ly/2UqiCwQ pic.twitter.com/G4WIVncbHp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Do you or one of your loved ones have
#GIST? Learn more about the importance of mutational testing via Mutation Matters: http://bit.ly/2SW92Bk pic.twitter.com/nDvA3y6xuX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#BlueCrew is motivated to identify new drug targets that expand the possibilities of#precisionmedicine. Learn more about our science: http://bit.ly/37GqTAi pic.twitter.com/ZYZrxnd7gm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We seek to design precision therapies that target the underlying molecular basis of disease. Learn more about our
#precisiontherapy approach: http://bit.ly/2GjkiA2 pic.twitter.com/LEAfNTXTDE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Keith, our head of US Precision Medicine, will be speaking at
#PMWC20#SiliconValley next week about our efforts to fuel rapid advances in#precisionmedicine. https://bit.ly/3agllhX pic.twitter.com/ifMB0eYNgs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sean and his team are committed to working closely with healthcare providers across the U.S. to help make a difference for patients with
#cancer and#rarediseases.pic.twitter.com/7ElBTIDwEx
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#GIST is well-established as a genomically driven disease. Hear Maria, our senior medical director, explain the benefits of mutational testing for this cancer.pic.twitter.com/xQYSHdKsVeHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Since our company’s inception, we’ve focused on building a scalable research platform that could yield multiple precision therapies for a wide range of diseases. Learn more about our commitment to advancing
#precisionmedicine:http://bit.ly/37GqTAiHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our annual mentoring program gives the
#BlueCrew opportunities to learn about functional areas different from their everyday roles. Check out our recent participants!#NationalMentoringMonthpic.twitter.com/ZtPboqbmJE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
While a number of mutations may cause
#GIST, KIT and PDGFRA are the primary drivers of the disease. Learn more: http://bit.ly/2SW92Bk pic.twitter.com/zkrr4ZwpnZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Do you know the differences between immunohistochemical (IHC) staining, which support the diagnosis of
#GIST, and mutational testing? Read more about both, courtesy of@LifeRaftGroup:http://bit.ly/2SYzJW1Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you’re planning to start
#GIST treatment, mutational testing can help determine the right therapy for your tumor type. Hear more from a clinical expert: http://bit.ly/2SW92Bk pic.twitter.com/lUNzllJ7p4Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re dedicated to providing robust support throughout patients’ treatment journey. We developed our patient support program to reflect this commitment; read more here: http://bit.ly/2sTv6SB pic.twitter.com/csqYuvnYCT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our Medical Director Brenton highlights the benefits of
#precisiontherapy, which aims to deliver the right treatment to the right patient.pic.twitter.com/IKvGg06Vc2Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're gratified to bring a new treatment option to
#GIST patient, which was made possible by the unwavering efforts of clinical investigators, trial participants, patient groups like@LifeRaftGroup & GIST Support International,#BlueCrew members past & present, and many others.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Michael Heinrich from
@OHSUKnight, who's an investigator in our#GIST clinical trials, highlights a new era of#precisionmedicine in GIST and the importance of mutational testing.pic.twitter.com/ajJiRovxYN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Tune in today at 4:30 p.m. ET for our live webcast to discuss our
@US_FDA approval: http://bit.ly/2R0xejs pic.twitter.com/K6vZCldfAo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today, we received
@US_FDA approval for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (#GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Learn more: http://bit.ly/2R0aKyZ pic.twitter.com/wiCSqHjsL2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$BPMC looks forward to joining others in the#biotech industry next week at the 38th Annual J.P. Morgan Healthcare Conference. Hope you to see you in San Francisco!pic.twitter.com/3Tj7Kem6Xr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.